These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10601285)

  • 1. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.
    He B; Kemppainen JA; Voegel JJ; Gronemeyer H; Wilson EM
    J Biol Chem; 1999 Dec; 274(52):37219-25. PubMed ID: 10601285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.
    He B; Kemppainen JA; Wilson EM
    J Biol Chem; 2000 Jul; 275(30):22986-94. PubMed ID: 10816582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2.
    He B; Bowen NT; Minges JT; Wilson EM
    J Biol Chem; 2001 Nov; 276(45):42293-301. PubMed ID: 11551963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
    Askew EB; Minges JT; Hnat AT; Wilson EM
    Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction.
    Bai S; He B; Wilson EM
    Mol Cell Biol; 2005 Feb; 25(4):1238-57. PubMed ID: 15684378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.
    He B; Gampe RT; Kole AJ; Hnat AT; Stanley TB; An G; Stewart EL; Kalman RI; Minges JT; Wilson EM
    Mol Cell; 2004 Nov; 16(3):425-38. PubMed ID: 15525515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.
    Alen P; Claessens F; Verhoeven G; Rombauts W; Peeters B
    Mol Cell Biol; 1999 Sep; 19(9):6085-97. PubMed ID: 10454556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements.
    Callewaert L; Verrijdt G; Christiaens V; Haelens A; Claessens F
    J Biol Chem; 2003 Mar; 278(10):8212-8. PubMed ID: 12509416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction.
    He B; Lee LW; Minges JT; Wilson EM
    J Biol Chem; 2002 Jul; 277(28):25631-9. PubMed ID: 12000757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors.
    Slagsvold T; Kraus I; Bentzen T; Palvimo J; Saatcioglu F
    Mol Endocrinol; 2000 Oct; 14(10):1603-17. PubMed ID: 11043576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FXXLF motif mediates androgen receptor-specific interactions with coregulators.
    He B; Minges JT; Lee LW; Wilson EM
    J Biol Chem; 2002 Mar; 277(12):10226-35. PubMed ID: 11779876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
    Zhou ZX; He B; Hall SH; Wilson EM; French FS
    Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor.
    Liu Q; Su S; Blackwelder AJ; Minges JT; Wilson EM
    J Biol Chem; 2011 Aug; 286(34):29951-63. PubMed ID: 21730049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
    Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
    Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.
    Estébanez-Perpiñá E; Moore JM; Mar E; Delgado-Rodrigues E; Nguyen P; Baxter JD; Buehrer BM; Webb P; Fletterick RJ; Guy RK
    J Biol Chem; 2005 Mar; 280(9):8060-8. PubMed ID: 15563469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of interdomain interactions of the androgen receptor.
    Wilson EM
    Methods Mol Biol; 2011; 776():113-29. PubMed ID: 21796524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.
    Powell SM; Christiaens V; Voulgaraki D; Waxman J; Claessens F; Bevan CL
    Endocr Relat Cancer; 2004 Mar; 11(1):117-30. PubMed ID: 15027889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
    Wang Q; Lu J; Yong EL
    J Biol Chem; 2001 Mar; 276(10):7493-9. PubMed ID: 11102454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
    Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
    Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.
    Dubbink HJ; Hersmus R; Verma CS; van der Korput HA; Berrevoets CA; van Tol J; Ziel-van der Made AC; Brinkmann AO; Pike AC; Trapman J
    Mol Endocrinol; 2004 Sep; 18(9):2132-50. PubMed ID: 15178743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.